CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 26 enrolled
Drug / intervention
quetiapine XR +1 moredrug
Likely dose
quetiapine XR 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00619892
NCT00619892Phase 4Completed
CompareCT.gov

An 8-week, Randomized, Double-Blind, Placebo-Controlled Trial of Seroquel SR Co-administration for SSRI-Resistant, Comorbid Panic Disorder

Indiana University·interventional·Posted Feb 21, 2008·Updated Jan 21, 2016

In Brief

A Phase 4 clinical trial evaluating quetiapine XR and placebo for Panic Disorder. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The primary objective of this study is to test the hypothesis that a SSRI plus quetiapine SR (Seroquel SR) will result in superior early (first 1-3 weeks of treatment) stabilization of panic symptoms in SSRI-resistant, comorbid Panic Disorder patients versus a SSRI plus placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPanic Disorder
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 21, 2008
Enrollment StartFeb 1, 2008
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.4 years ago

Interventions

quetiapine XRdrug

Subjects will receive daily dosing at night, with a flexible dosing schedule, 50-400 mg.

placebodrug

Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.